Related Experiment Video
Updated: Jun 23, 2025
Micro-dissection of Enamel Organ from Mandibular Incisor of Rats Exposed to Environmental Toxicants
Published on: March 29, 2018
Molar Incisor Hypomineralization: Optimizing Treatment Protocols for Hypersensitivity: A Randomized Clinical Trial
Elena Bardellini1, Francesca Amadori1, Laura Rosselli1
1Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Pl. Spedali Civili 1, 25123 Brescia, Italy.
Treating dentin hypersensitivity (DH) in children with molar incisor hypomineralization (MIH) is crucial. Combining casein phosphopeptide plus amorphous calcium phosphate fluoride (CPP-ACPF) mousse and photo-bio-modulation therapy (PMBT) offers the most effective relief for DH.
Area of Science:
- Pediatric Dentistry
- Dental Biomaterials
- Pain Management
Background:
- Dentin hypersensitivity (DH) is prevalent in pediatric molar incisor hypomineralization (MIH) due to enamel defects.
- Effective management strategies for DH in MIH patients are needed.
Purpose of the Study:
- To compare the efficacy of casein phosphopeptide plus amorphous calcium phosphate fluoride (CPP-ACPF) mousse and photo-bio-modulation therapy (PMBT) alone and in combination for treating DH in children with MIH.
Main Methods:
- A three-arm randomized controlled clinical trial involving 39 children (aged 6-14) with MIH and DH.
- Group A: CPP-ACPF mousse + sham light therapy. Group B: Placebo mousse + PMBT. Group C: CPP-ACPF mousse + PMBT.
- Dentin hypersensitivity assessed using a Visual Analogue Scale (VAS) at multiple time points.
Main Results:
- Both CPP-ACPF mousse and PMBT demonstrated desensitizing effects.
- PMBT showed a greater immediate effect.
- The combination therapy (Group C) resulted in statistically significant lower VAS scores compared to individual therapies after the first session (p=0.0001) and at 28 days (p=0.0005).
Conclusions:
- Combined CPP-ACPF mousse and PMBT is highly effective in reducing DH in pediatric patients with MIH.
- This combination therapy offers enhanced clinical outcomes for managing DH in this population.
